December 2019—Abbott announced that its Architect Stat High Sensitivity Troponin-I blood test has received clearance from the FDA for use on the Architect analyzer.
The test measures very low levels of troponin, allowing clinicians to evaluate heart attack in patients within two to four hours of admission.
”As one of the most widely researched high sensitivity troponin tests, this technology could help address several challenges in emergency departments today, including overcrowding and more accurately identifying heart attacks in women,” Agim Beshiri, MD, Abbott’s senior medical director of global medical and scientific affairs, diagnostics, said in a company press release.
Abbott, 224-667-6100